A Phase 2 interventional study of C-CAR168 in Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) and Autoimmune Diseases, sponsored by AbelZeta Inc.. Not yet recruiting. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AbelZeta Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory lupus nephritis who are not responding to standard therapy.
Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of C-CAR168. Participants will be followed for 104 weeks (approximately 2 years) to evaluate renal response, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.
This is a global, multicenter, single-arm, open-label Phase 2 study evaluating C-CAR168, an autologous dual-targeted anti-CD20/BCMA CAR T-cell therapy, in participants with biopsy-confirmed refractory lupus nephritis who are not responding to standard therapy.
Participants will undergo screening, leukapheresis, manufacture of autologous C-CAR168, lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide, followed by a single intravenous infusion of C-CAR168.
The study begins with a safety run-in involving the first five participants. Following review by the Safety Monitoring Committee (SMC), enrollment of the remaining participants may proceed if predefined safety criteria are met.
Participants will be followed for 104 weeks after infusion for evaluation of efficacy, safety, pharmacokinetics, pharmacodynamics, immunologic biomarkers, and patient-reported outcomes. Participants will subsequently be invited to enroll in a separate long-term follow-up study for continued safety monitoring consistent with FDA recommendations for gene-modified cellular therapies.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
This study's planned enrollment of 50 is close to the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Browse Lupus Nephritis studies →AbelZeta Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive: * Leukapheresis * Fludarabine * Cyclophosphamide * Single intravenous infusion of C-CAR168
Drug: C-CAR168
Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion at a target dose of 1 × 10\^6 CAR-positive T cells/kg (maximum dose 100 × 10\^6 CAR-positive T cells).
Complete Renal Response (CRR)
Proportion of participants achieving Complete Renal Response according to protocol-defined criteria.
Time frame: Week 65 (Month 15)
Incidence and severity of adverse events (AEs)
Evaluate the incidence, severity, and relationship of adverse events following C-CAR168 infusion, graded according to NCI CTCAE Version 6.0.
Time frame: Through Week 104 (Month 24)
incidence of serious adverse events (SAEs)
Evaluate the incidence of serious adverse events following treatment.
Time frame: Through Week 104 (Month 24)
Incidence and severity of cytokine release syndrome (CRS)
Assess CRS according to American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria.
Time frame: Through Week 104 (Month 24)
Incidence and severity of immune effector cell-associated neurotoxicity syndrome (ICANS)
Assess ICANS according to ASTCT consensus grading criteria.
Time frame: Through Week 104 (Month 24)
Duration of Complete Renal Response (CRR)
Evaluate the maintenance of complete renal response without relapse, flare, or rescue medication.
Time frame: Through Week 104 (Month 24)
Partial Renal Response (PRR)
Evaluate the proportion of participants achieving partial renal response.
Time frame: Through Week 104 (Month 24)
Primary Efficacy Renal Response (PERR)
Evaluate the proportion of participants achieving Primary Efficacy Renal Response.
Time frame: Through Week 104 (Month 24)
Reduction in proteinuria
Evaluate the proportion of participants achieving at least a 75% reduction in urine protein-to-creatinine ratio (uPCR).
Time frame: Through Week 104 (Month 24)
Time to renal response
Evaluate the time to achievement of Complete Renal Response, Partial Renal Response, and Primary Efficacy Renal Response.
Time frame: Through Week 104 (Month 24)
Pharmacokinetics of C-CAR168 measuring quantitative polymerase chain reaction (qPCR)
Characterize CAR T-cell expansion and persistence using qPCR
Time frame: Through Week 104 (Month 24)
Pharmacokinetics of C-CAR168 utilizing flow cytometry
Characterize T-cell expansion and persistence utilizing flow cytometry
Time frame: Through Week 104 (Month 24)
Change in patient-reported outcomes (PROs)
Evaluate changes in health-related quality of life using PROs.
Time frame: Through Week 104 (Month 24)
DORIS remission
Evaluate the proportion of participants achieving the Definition of Remission in SLE (DORIS).
Time frame: Though Week 104 (Month 24)
Progressive renal failure
Evaluate the proportion of participants experiencing progressive renal failure as measured by estimated glomerular filtration rate (eGFR).
Time frame: Through Week 104 (Month 24)
Corticosteroid reduction
Evaluate the proportion of participants receiving less than 5 mg/day prednisone equivalent.
Time frame: Through Week 104 (Month 24)
Lupus disease flare
Evaluate the proportion of participants experiencing disease flare according to the SELENA-SLEDAI Flare Index.
Time frame: Through Week 104 (Month 24)
Immunologic response
Evaluate changes in anti-double stranded DNA antibodies, circulating B cells, plasma cells, and complement C3/C4 levels.
Time frame: Through Week 104 (Month 24)
Exploratory Biomarker Assessments
Evaluate exploratory biomarkers associated with treatment with C-CAR168 and their relationship to efficacy and safety. Biomarkers include C-CAR168-related and disease-related markers in blood, urine, and optional tissue specimens, including immune cell populations, gene expression, cytokines, and urinary biomarkers.
Time frame: Through Week 104 (Month 24)
No study locations are listed for this record.
Plan to share: No — Individual participant data collected during this study will not be made available to other researchers.
Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.